AVM
TXG icon

Arch Venture Management’s 10x Genomics TXG Stock Holding History

Arch Venture Management’s Portfolio TXG Stock Details TXG Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$4.62M Sell
217,834
-519,705
-70% -$10.4M 0.68% 8
2025
Q4 		$12M Buy
+737,539
New +$11.1M 1.85% 8

Other funds holding TXG

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
QCM
Quantinno Capital Management New York $59.9B AUM 28.07% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Arch Venture Management's TXG Position: Q1 2026 in Review

Arch Venture Management reduced its 10x Genomics (TXG) stake by 70% in Q1 2026, selling an estimated $10.4M and leaving 217,834 shares worth $4.62M. The position accounts for 0.68% of the portfolio, ranked #8.

Arch Venture Management first reported a position in TXG in Q4 2025 and has held it in 2 quarters since. The position peaked at $12M in Q4 2025. 329 funds tracked by Wall St. Rank hold TXG as of Q1 2026.

  • Arch Venture Management held 217,834 shares of 10x Genomics worth $4.62M as of Q1 2026.
  • Arch Venture Management sold 519,705 10x Genomics shares in Q1 2026, an estimated $10.4M.
  • 10x Genomics made up 0.68% of Arch Venture Management's portfolio in Q1 2026, its #8 holding.
  • Arch Venture Management first reported a position in 10x Genomics in Q4 2025 and has held it in 2 quarters since.
  • Arch Venture Management's 10x Genomics position peaked at $12M in Q4 2025.
  • 329 funds tracked by Wall St. Rank held 10x Genomics as of Q1 2026.

Based on Arch Venture Management's 13F filing for Q1 2026, filed 15 May 2026.